Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older Adults

An RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said

An experimental vaccine from Moderna Inc. significantly reduced the risk of aamong older adults in a large clinical trial, the latest promising sign in drugmakers’ efforts to fight the deadly RSV virus.

Citing the results, the Cambridge, Mass., company said Tuesday it would apply in the coming months for U.S. regulatory approval to sell its vaccine against RSV, which stands for respiratory syncytial virus. If regulators approve the vaccine, it could become available by early 2024, the company said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJhealth /  🏆 413. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »

Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study FindsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »

Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »

Moderna stock rallies 5% after respiratory virus vaccine trial meets endpointsModerna Inc. shares rallied in the extended session Tuesday after the biotech drug company said results from a late-stage clinical trial for its respiratory...
Read more »

British chemical firm Ineos nears deal to buy Sika assets, Bloomberg reportsBritish chemical firm Ineos is nearing a deal to buy assets being sold by Sika AG to appease antitrust regulators, Bloomberg News reported on Sunday, citing people familiar with the matter.
Read more »